In the new study, 50 NAFLD patients with pre-diabetes or early diabetes were randomized into two groups: one received a 100 milligram oral dose of sitagliptin daily for 24 weeks, the other received a placebo. (sciencedaily.com)
In 2007, for example, new drugs such as sitagliptin (brand name Januvia, $ 160 per average prescription) and exenatide (Byetta, $ 202) made up eight percent and four percent, respectively, of all physician office visits where a diabetes drug was prescribed. (uchospitals.edu)
As well as six times the increase in reported cases of pancreatitis, a 2.7 times higher rate of pancreatic cancer in individuals on sitagliptin was also found and a 2.9 times greater rate of pancreatic cancer in individuals making use of exenatide, in comparison to the other therapies. (ahealthblog.com)